Connect Biopharma's Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China

Reuters

07/09

<a href="https://laohu8.com/S/CNTB">Connect Biopharma</a>'s Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China

Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced that its exclusive licensee in China, Simcere Pharmaceutical Co., Ltd., has submitted a New Drug Application for rademikibart to the National Medical Products Administration of China. This submission is for the treatment of atopic dermatitis in adults and adolescents. As part of their collaboration, Connect Biopharma is set to receive milestone payments and royalties based on net sales in Greater China. The application submission marks a significant step forward in bringing a potentially transformative treatment for atopic dermatitis to the Chinese market, addressing the needs of an estimated 70 million patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491282-en) on July 09, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550630162"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550630162\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550630162?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550630162","market":"us","top_or_hot":-1,"title":"Connect Biopharma's Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a>'s Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced that its exclusive licensee in China, <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Co., Ltd., has submitted a New Drug Application for rademikibart to the National Medical Products Administration of China. This submission is for the treatment of atopic dermatitis in adults and adolescents. As part of their collaboration, Connect Biopharma is set to receive milestone payments and royalties based on net sales in Greater China. The application submission marks a significant step forward in bringing a potentially transformative treatment for atopic dermatitis to the Chinese market, addressing the needs of an estimated 70 million patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491282-en) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Connect Biopharma's Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConnect Biopharma's Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-09 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CNTB\">Connect Biopharma</a>'s Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced that its exclusive licensee in China, <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Co., Ltd., has submitted a New Drug Application for rademikibart to the National Medical Products Administration of China. This submission is for the treatment of atopic dermatitis in adults and adolescents. As part of their collaboration, Connect Biopharma is set to receive milestone payments and royalties based on net sales in Greater China. The application submission marks a significant step forward in bringing a potentially transformative treatment for atopic dermatitis to the Chinese market, addressing the needs of an estimated 70 million patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491282-en) on July 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL6KmGg0:1","article_id":"2550630162","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550630162","pubTimestamp":1752066026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced that its exclusive licensee in China, Simcere Pharmaceutical Co., Ltd., has submitted a New Drug Application for rademikibart to the National Medical Products Administration of China. This submission is for the treatment of atopic dermatitis in adults and adolescents. As part of their collaboration, Connect Biopharma is set to receive milestone payments and royalties based on net sales in Greater China. The application submission marks a significant step forward in bringing a potentially transformative treatment for atopic dermatitis to the Chinese market, addressing the needs of an estimated 70 million patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CNTB":"康乃德生物医药","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK1583":"高瓴概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","02096":"先声药业","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK1191":"制药","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Connect Biopharma合作伙伴先声药业在中国提交Rademikibart治疗特应性皮炎新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9,"CNTB":0.9,"NDAQ":0.9},"content_text":"Connect Biopharma's Partner Simcere Submits New Drug Application for Rademikibart for Atopic Dermatitis Treatment in China\n    \n\n        Connect Biopharma Holdings Ltd., a clinical-stage biopharmaceutical company, has announced that its exclusive licensee in China, Simcere Pharmaceutical Co., Ltd., has submitted a New Drug Application for rademikibart to the National Medical Products Administration of China. This submission is for the treatment of atopic dermatitis in adults and adolescents. As part of their collaboration, Connect Biopharma is set to receive milestone payments and royalties based on net sales in Greater China. The application submission marks a significant step forward in bringing a potentially transformative treatment for atopic dermatitis to the Chinese market, addressing the needs of an estimated 70 million patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9491282-en) on July 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}